FDA Approves Bard Stent Systems

C.R. Bard has received FDA approval for its LifeStent FlexStar and FlexStar XL vascular stent systems. Used to treat occlusive disease in native superficial femoral arteries and proximal popliteal arteries, the devices will be marketed by the Bard Peripheral Vascular Division. At 170 mm, the LifeStent is the longest stent available in the U.S. and will allow long and diffuse lesions to be treated with a single stent, which should reduce costs and improve clinical outcomes, the company said.